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Glioblastoma multiforme (GBM) is the most common and
malignant type of primary brain tumor, exhibiting poor
response to therapy and seemingly inevitable recurrence.
$e current standard of care for treating newly diagnosed
GBM is maximal safe resection followed by radiation with
concurrent and adjuvant temozolomide, a regimen which
has been shown to improve median overall survival (12.1
months vs. 14.6 months) and 2-year (27.2% vs. 10.9%) and 5-
year (10.9% vs. 1.9%) survival rates when compared with
radiation alone.
$is special issue was aimed at updating researchers on
current topics and progress made in basic, preclinical, and
clinical glioblastoma research. It also provided a platform for
pharmaceutical and translational scientists to submit orig-
inal research articles, review articles, and clinical studies,
focusing on the evaluation of new molecular pathways as
pharmacological targets for treatment strategies which may
improve the management of aggressive, drug-resistant
GBM, in the hope that a deeper knowledge of GBM biology
may eventually lead to effective targeted therapeutic ap-
proaches based on the inhibition of tumor-specific proteins
or molecular pathways.
Unfortunately, this neoplasia contains an elevated per-
centage of transformed, self-maintaining, multipotent, tu-
mour-initiating cancer stem cells, mainly present in highly
hypoxic areas of the tumor in conjunction with palisading
necrosis. Despite multimodal therapies, prognosis for GBM
is still dismal. Many features contribute to this therapeutic
challenge, including high intratumoral and intertumoral
heterogeneity, resistance to therapy, migration and invasion,
and immunosuppression. Nevertheless, with the advent of
novel high-throughput drug screening technologies, to-
gether with a growing body of genetic and transcriptomic
information, significant progress has been made to under-
stand the molecular and immunological signatures under-
lying the pathology of glioblastoma.
We received 11 reports for publication, accepting 7 after
peer review. A brief summary of all accepted papers is
provided below.
Elevated invasive capacity is one of the key tumoral
features associated with treatment resistance, recurrence,
and poor overall survival in GBM. $e research group of
Akira Ara at the Gifu University Graduate School of
Medicine (Gifu, Japan) reviewed treatment strategies based
on histological targets against invasive and resistant GBM
using the classification of the “secondary structures of
Scherer.” One of the main reasons that gliomas are not cured
by surgery is the topographically diffuse nature of the dis-
ease. In addition to the high degree of intratumor variability
mentioned previously, the extensive spreading of malignant
tumor cells within the brain parenchyma results in an in-
ability to completely resect this tumor. Hans-Joachim
Scherer was a pioneer in the study of glioma growth patterns.
In 1940, Scherer described the appearance and behavior of
glioma cells migrating away from the main tumor mass
through the brain parenchyma. $e patterns of glioma cell
infiltration have since been referred to as the “secondary
structures of Scherer.” Infiltrating glioma cells migrate
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through the normal parenchyma, collect just below the pial
margin (subpial spread), surround neurons and vessels
(perineuronal and perivascular satellitosis), and migrate
through the white matter tracts (intrafascicular spread).
Examples of observed secondary structures include peri-
neuronal growth (perineuronal satellitosis), surface/subpial
growth, perivascular growth, and intrafascicular growth. In
order to develop therapeutic interventions to mitigate gli-
oma cell migration, it is important to understand the bio-
logical mechanisms underlying the formation of these
secondary structures. $e review examined new molecular
pathways based on the histopathological evidence of GBM
invasion as a major prognostic factor in the high recurrence
rate for GBMs. Specific molecular parameters, in addition to
traditional histopathological analysis, have been used to
define tumor classification in the revised 4th edition of the
WHO Classification of CNS tumors, published in 2016.
Detailed histopathological analysis based on the combina-
tion of molecular parameters with traditional analytical
methods can now be used to evaluate efficacy of targeted
therapies against cellular and genetic heterogeneity within
both invasive and drug-resistant glioblastoma.
$e molecular machinery underlying GBM invasiveness
involves an intricate network of signaling pathways and in-
teractions with the extracellular matrix and neighboring host
cells. In this special issue, a collaboration amongst researchers
from the Department of Neurological Surgery and Spine Unit
and Genetics Unit (Hospital Universitario and Instituto de
Investigacio´n Marque´s de Valdecilla in Santander, Spain), the
Division of Neurosurgery (University of Toronto, Canada),
and the MacFeeters-Hamilton Center for Neuro-Oncology
Research (Princess Margaret Cancer Center in Toronto,
Canada) is reported, reviewing and highlighting the molec-
ular and clinical hallmarks of invasion in GBM. In this paper,
C. Vela´squez et al. review data on adhesion molecules, ex-
tracellular matrix (ECM) components, epithelial-to-mesen-
chymal transition (EMT), cytoskeleton-remodeling proteins,
cross-talk with host cells and immune modulation, as well as
the signaling pathways associated with GBM invasion (in-
cluding those involving receptor tyrosine kinases, Wnt (both
canonical and β-catenin-independent pathways), hedgehog-
GLI1, and nuclear factor-κB. $e authors analyze the clinical
implications of GBM invasiveness and assess GBM invasion
in the clinical setting, by imaging GBM invasion intra-
operatively to guide surgical resection and radiation therapy
of the infiltrative tumor.
G. Steponaitis et al., Laboratory of Molecular Neuro-
Oncology, Lithuanian University of Health Sciences (Kau-
nas, Lithuania), elucidated the oncosuppressive role of runt-
related transcription factor 3 (RUNX3) in human astrocy-
tomas. RUNX3 is a tumor suppressor gene whose inacti-
vation was shown to be related to carcinogenesis in several
cancers. Methylation status and protein expression levels of
RUNX3 were measured by methylation-specific PCR and
Western blotting in tissues harvested from normal tissues
and glioma of different grades. $ese researchers demon-
strate that RUNX3 gene methylation and protein expression
downregulation are glioma malignancy-dependent and
contribute to tumor progression. Importantly, these authors
also demonstrated that re-expression of RUNX3 in the
glioblastoma U87-MG cell line decreased cell viability in
vitro. However, it remains to be demonstrated whether
transfection of RUNX3 can reduce tumor progression and
increase survival in vivo after injection of cells in nude mice.
E. Berney et al., Departments of Physiology/Anatomy
and Pediatrics, University of North Texas Health Science
Center (Fort Worth, Texas, USA), reported data on the
scavenger receptor class B type 1 (SR-B1) as a potential target
for treating glioblastoma. $ese studies involved the eval-
uation of reconstituted high-density lipoprotein (rHDL)
nanoparticles (NPs) as delivery agents for the drug mam-
malian target of rapamycin (mTOR) inhibitor everolimus
(EVR) to GBM cells. Cytotoxicity studies and assessment of
downstream effects, including apoptosis, migration, and cell
cycle events, were probed, in relation to the expression of
SR-B1 by GBM cells. $e authors revealed that rHDL/EVR
formulation was 185 times more potent than free EVR
against the high SR-B1 expressing GBM cell line LN 229. In
addition, cell cycle analysis revealed that rHDL/EVR-treated
LN229 cells had a 5.8 times higher apoptotic cell population
than those treated with EVR. $e sensitivity of GBM cells to
EVR treatment was also strongly correlated with SR-B1
expression. So, delivering EVR and likely other agents, via a
biocompatible transport system targeted to the SR-B1 re-
ceptor, could lead to effective personalized therapy of GBM.
C. Cilibrasi et al., School of Medicine and Surgery
(University of Milano-Bicocca), in collaboration with the
NeuroMI, Milan Center of Neuroscience, the Departments
of Neurology and Neuroscience, San Gerardo Hospital, the
Department of Neurology and Neurosurgery, Montreal
Neurological Institute and Hospital (McGill University,
Montreal, Quebec, Canada), the International Center for
Digestive Health (ICDH), University ofMilano-Bicocca, and
the Genome Damage and Stability Center, School of Life
Sciences, University of Sussex, UK, showed that a ploidy
increase promotes sensitivity of glioma stem cells to Aurora
kinase inhibition, investigating the effect of Aurora kinase
inhibition in five glioma stem cell lines isolated from glio-
blastoma patients. As expected, cell lines responded to the
loss of Aurora kinase with cytokinesis failure andmitotic exit
without cell division. Surprisingly, this resulted in a pro-
liferative arrest in only two of the five cell lines. Sensitive cell
lines entered a senescent/autophagic state following aberrant
mitotic exit, while the nonsensitive cell lines continued to
proliferate. $is senescence response did not correlate with
TP53 mutation status but only occurred in the cell lines with
the highest chromosome content. Repeated rounds of Au-
rora kinase inhibition caused a gradual increase in chro-
mosome content in the resistant cell lines, eventually leading
to a similar senescence response and proliferative arrest. $e
results suggest that a ploidy threshold is the main deter-
minant of Aurora kinase sensitivity in TP53 mutant glioma
stem cells. $us, ploidy could be used as a biomarker for
treating glioma patients with Aurora kinase inhibitors in
TP53 mutant glioma stem cells. Further research will be
necessary to explore the mechanism of ploidy-induced se-
nescence and the precise reason why a particular ploidy
threshold appears to trigger this response.
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A. Menezes et al. investigated the impact of HDAC
activity on GBM cell behavior and plasticity by live cell
imaging. $ese researchers knocked down HDAC activity
pharmacologically using two different inhibitors (TSA and
SAHA) in two different tumor cell types: a commercial GBM
cell line (U87-MG) and a primary tumor (GBM011). Upon
72 hours of in vitro HDAC inhibitor treatment, GBM cells
presented a very unusual elongated cell shape due to the
formation of tunneling tubes which appeared independent
of TGFβ-induced EMT. Live cell imaging revealed that
voltage-sensitive Ca++ signaling was disrupted upon HDAC
activity blockade. $is behavior was coupled to down-
regulation of vimentin and connexin gene expression,
suggesting that HDAC activity blockade downgrades GBM
aggressiveness due to tumor cell competence and plasticity
modulation in vitro. To investigate these effects, GBM
oncospheres were xenografted into the chick developing
neural tube. Remarkably, when placed within the developing
neural tube, HDAC inhibitor-treated GBM cells ectopically
expressed HNK-1, a tumor suppressor marker tightly cor-
related to increased survival of patients. $ese results de-
scribe, for the first time in the literature, the relevance of
HDAC inhibition to in vivo tumor cell morphology and
competence in an appropriate response to environmental
cues. Ultimately, the results highlight the relevance of
chromatin remodeling for tumor cell plasticity and shed
light on the clinical targeting of the epigenome in GBM
therapy.
$e blood-brain barrier (BBB) is an anatomical functional
unit created by characteristic endothelial cells forming blood
vessels within the central nervous system. $e main function
of the BBB is protecting brain tissue from harmful elements
present in the blood while still allowing the passage of sub-
stances necessary for metabolic functions. BBB endothelial
cells form a continuous and nonfenestrated endothelium,
sealed by occluding cellular junctions (tight junctions), whose
compactness prevents the passage of hydrophilic and high-
molecular weight substances from the blood to the brain
parenchyma, performing filtration which is much more se-
lective than that of endothelial cells in the capillaries of other
parts of the body. Further structural features of the BBB
include projections of astrocytic cells, called astrocytic pe-
duncles (also known as the “glial limiting” membrane), which
surround the endothelial cells of the BBB, providing an ad-
ditional “barrier.” Although the structure of the BBB is often
impaired in GBM, it is thought that BBB penetrance still
represents a serious barrier to drug delivery to the tumor.
Different methods have been exploited to bypass the BBB and
increase the tumor uptake of therapeutic agents. In this issue,
M. Shi and L. Sanche of the Department of Radiation On-
cology, School of Medicine, Hangzhou, China and the De-
partment of Nuclear Medicine and Radiobiology, Universite´
de Sherbrooke, Canada, evaluated the efficacy of convection-
enhanced delivery (CED), using multiple drugs with different
antitumor mechanisms, concomitant with radiation and
chemotherapy. Importantly, the simultaneous use of these
procedures demonstrated supra-additive effects over standard
drug treatments, representing a promising modality for brain
tumor therapy. $e authors also evaluated the efficacy of
different CED-based strategies as part of Phase II and III
clinical trials. CED bypasses the BBB, increases drug uptake
by the tumor, and reduces systemic toxicity.
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